Corvus Pharmaceuticals Inc (CRVS): Crescendo and Biontech appear to be targ...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	10
Posts	474
Boards Moderated	0
Alias Born	02/10/2006

flatlander_60048

Re: None

Thursday, 04/13/2023 9:47:40 AM

Thursday, April 13, 2023 9:47:40 AM

Crescendo and Biontech appear to be targeting the development of novel, targeted T cell enhancing therapeutics for treatment of cancer. BionTech looks to be exploring several approaches " mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules".. They are in early clinical trial for prostate cancer..

I wonder to what extent CRVS has crossed BionTech's radar. Looking at the links it looks like Biontech has collaborations with Genmab, so monoclonal antibody approaches to T cell modulation have to be high on their list.

FL

https://finance.yahoo.com/news/angle-plc-announces-pharma-services-060000021.html

https://investors.biontech.de/news-releases/news-release-details/biontech-and-crescendo-biologics-announce-global-collaboration